Anti-Respiratory Syncytial Virus (Clone: RSV-12I1) - Biotin - 250 µg

Primary Monoclonal Antibodies>Infectious Diseases|Monoclonal Antibodies|Recombinant Antibodies

Standard Overnight on Blue Ice.

Respiratory syncytial virus (RSV) is a common respiratory virus that infects the majority of children by two years old1, 2. While usually mild, RSV can be serious in infants and older adults and is the leading cause of bronchiolitis and pneumonia in children less than one year of age in the United States1. Antibodies have been described that bind and neutralize RSV fusion (F) protein2-4. RSV F protein is a type I integral membrane protein that is synthesized as a 574 amino acid inactive precursor, assembled into a trimer, post-translationally modified, then cleaved to produce F1, F2, and intervening peptide pep273. Functional F protein has both pre- and post-fusion conformations. RSV F protein is highly conserved among RSV isolates from both A and B subgroups3 and is the primary target for antiviral drug development3 with several antigenic regions capable of introducing neutralizing antibodies2. RSV-12I1 was generated from human donors using human hybridoma technology4. Transformed B cells were screened by ELISA against recombinant post-fusion RSV A2 F protein and isolated by single-cell flow cytometric sorting. RSV-12I1 failed to show neutralization activity against RSV strain A2 in a plaque reduction neutralization assay. RSV-12I1 did bind to both pre- and post-fusion F protein in an ELISA binding assay, favoring the post-fusion conformation. Competition-binding studies showed that RSV-12I1 targets antigenic site II, which is the target of palivizumab, an antiviral monoclonal antibody licensed as a prophylactic treatment. RSV-12I1 readily competed with RSV-14N4 on post-fusion F, but the competition was less pronounced on pre-fusion F. RSV-12I1 also competed with palivizumab on post-fusion F in a palivizumab competition assay. Saturation alanine scanning mutagenesis identified residues Leu467 and Lys470 as critical for RSV-12I1 binding. Binding was not detected to scaffolded epitopes containing site II. The RSV-12I1 isotype is IgG1.

0.5 mg/ml

F protein is a surface glycoprotein